We serve Chemical Name:6-Dimethylamino-4-(1H)-Pyrimidinone CAS:1124-21-6 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Dimethylamino-4-(1H)-Pyrimidinone
CAS.NO:1124-21-6
Synonyms:4-Pyrimidinol, 6-(dimethylamino)-;6-(Dimethylamino)-4(1H)-pyrimidinone
Molecular Formula:C6H9N3O
Molecular Weight:139.155
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:304.2±22.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.604
PSA:
Exact Mass:139.074554
LogP:-0.24
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 4-Pyrimidinol, 6-(dimethylamino)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-(Dimethylamino)-4(1H)-pyrimidinone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Pyrimidinol, 6-(dimethylamino)- Use and application,4-Pyrimidinol, 6-(dimethylamino)- technical grade,usp/ep/jp grade.
Related News: With the improvement of people’s living standards and the aging degree, the demand for medicines has been increasing for a long time. Therefore, the transfer from finished medicines to bulk medicines has greatly promoted the demand for bulk medicines. 6-Dimethylamino-4-(1H)-Pyrimidinone manufacturer At present, Linhai, Zhejiang Province, has established a national chemical raw material base in Zhejiang Province, which is the earliest and largest gathering area of ??domestic chemical raw material medicines and pharmaceutical intermediate industries. 6-Dimethylamino-4-(1H)-Pyrimidinone supplier The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 6-Dimethylamino-4-(1H)-Pyrimidinone vendor The Biogen Inc (BIIB.O) drug, Aduhelm, was authorized based on evidence that it can reduce brain plaques, a likely contributor to Alzheimer’s, rather than proof that it slows progression of the lethal mind-wasting disease. 6-Dimethylamino-4-(1H)-Pyrimidinone factory During analysis of the clinical trial data, the researchers realized that about a third of the participants had low levels of abnormal tau protein, which makes them not very suitable for evaluating the effects of a treatment halting the progression of tau pathology.
